Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 12, 2024

Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.

Episodes in this series

Video 1 - "Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2"

EP. 1 Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Video 2 - "Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3"

EP. 2 Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Video 3 - "Identifying Risk to Enable Early Detection of Type 1 Diabetes "

EP. 3 Identifying Risk to Enable Early Detection of Type 1 Diabetes

Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"

EP. 4 Challenges in Autoantibody Screening for Type 1 Diabetes

Video 5 - "Strategies for Preventing Progression of Early-Stage Type 1 Diabetes"

EP. 5 Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"

EP. 6 Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"

EP. 7 Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man having heart attack - dragonstock - stock.adobe.com

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

ByPearl Steinzor

July 22nd 2026

David Zhang

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 22nd 2026

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

ByBrooke McCormick

July 22nd 2026

David Zhang

Real-World PRS Data Advance IPF Risk Prediction, Diagnosis: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 21st 2026

mantle cell lymphoma | Image: Perla Vicari / ASH Image Bank

Case Studies Focus on Glofitamab as Bridge to CAR T in MCL

July 20th 2026

Trending on AJMC

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial